Seeking Alpha

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

- The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA ® for the treatment of locally advanced or metastatic solid tumors - The study of ...
streetinsider

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy- The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy ...
Mena FN

Antengene Enters Into A Global Clinical Collaboration With MSD To Evaluate ATG-037 (CD73 Inhibitor) In Combination With KEYTRUDA® (Pembrolizumab)'

Antengene Corporation Limited ( 'Antengene' SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing ...
The Globe and Mail

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

- The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA ® for the treatment of locally advanced or metastatic solid tumors ...